2076975 2077203
최종편집 2024-03-29 13:17 (금)
제1회 원자력의학원/슬론 케터링 공동 컨퍼런스(10/9~11)
상태바
제1회 원자력의학원/슬론 케터링 공동 컨퍼런스(10/9~11)
  • 의약뉴스
  • 승인 2003.09.30 00:00
  • 댓글 0
이 기사를 공유합니다


□ 일 시 : 2003년 10월 9일(목) ∼ 10월 11일(토)
□ 장 소 : 원자력의학원 국가방사선비상진료센터 강당
□ 연수평점 : 대한의사협회 5평점/1일당
□ 등록비 : 무료, 사전 등록자에 한해 기념품 증정
□ 문의 및 사전등록 : 02-970-1605, pr@kcch.re.kr/www.kcch.re.kr

- 프로그램 -
■ 2003년 10월 9일(목)
"Experimental Molecular Targets for Treatment of Cancer"

08:30-09:00 Registration
09:00-09:10 Opening remarks (Shim Youn-Sang, MD, Thomas Fahey, MD)

Session I (Chairman: Jang Ja-Jun, MD)
09:10-09:40 Intensity modulated radiotherapy and beyond(C. Clifton Ling, PhD)
09:40-10:00 The mechanisms of HSP25-mediated radioresistance(Lee Yun-Sil, PhD)
10:00-10:20 Alteration of gene expression during radiation-induced tumorigenesis revealed by microarray(Kang Chang-Mo, PhD)
10:20-10:40 Increased radiosensitivity of the radioresistant MDA-MB-231 breast carcinoma cell line by N-acetylphytosphingosine(Yun Yeon-Sook, PhD)
10:40-10:50 Coffee break

Session II (Chairman: Park Gil-Hong, MD)
10:50-11:10 Antitumor mechanism of arsenic trioxide and sulindac(Park In-Chul, PhD)
11:10-11:40 Normal tissue damage: Cellular and molecular targets(Zvi Fuks, MD)
11:40-12:00 Role of phosphoinositide 3-kinase in the generation and actions of reactive oxygen intermediates(Um Hong-Duck, PhD)
12:00-12:20 Acting mechanism of sphingolipid metabolites in apoptosis signaling
(Lee Su-Jae, PhD)
12:20-13:20 Lunch

Session III (Chairman: Lee Jung-Young, MD)
13:20-14:00 Image guided radiation/Gene therapy targeting tumor hypoxia
(Gloria Li, PhD)
14:00-14:20 The role of cyclooxygenase(COX) and COX inhibitors on the survival of cancer cells(Hong Sung-Hee, PhD)
14:20-14:50 Biological images and conformality for IMRT(C. Clifton Ling, PhD)
14:50-15:10 Current research and custom services of NREMC's biodosimetry team
(Kim Tae-Hwan, PhD)
15:10-15:20 Coffee break

Session IV (Chairman: Lim In-Kyoung, MD)
15:20-15:40 Telomerase as an anticancer-therapeutic target(Lee Kee-Ho, PhD)
15:40-16:00 Diversity of TGF-beta signaling in cancer cells(Son Young-Sook, PhD)
16:00-16:30 Targets for radiation in the induction of tumor damage: Tissue clonagens vs. microvascular endothelium(Zvi Fuks, MD)


■ 2003년 10월 10일(금)
"Diagnosis and Treatment of Lung Cancer: Standard and New Trends"

08:30-09:00 Registration
09:00-09:05 Opening remarks (Shim Youn-Sang, MD)

Presidential Address
09:05-09:20 History of the development of the first comprehensive cancer center in America(Thomas Fahey, MD)
09:20-09:30 KIRAMS 40 years dedicated to cancer patient care in Korea
(Lee Soo-Yong, MD)

Session I. Diagnosis and Early Detection (Chairman: Kim Young-Whan, MD)
09:30-10:00 Experience with rapid CT scanning for screening patients at high risk for lung cancer*(Daniel Libby, MD)
10:00-10:20 Fusion PET/CT imaging in lung cancer(Cheon Gi-Jeong, MD)
10:20-10:40 PET imaging in thoracic malignancies(Robert Downey, MD)
10:40-11:00 New approaches to evaluating the solitary pulmonary nodule
(Daniel Libby, MD)
11:00-11:20 Molecular diagnosis of lung cancer using methylation abnormalities in sputum sample(Jang Se-Jin, MD)
11:20-11:30 Discussion
11:30-13:00 Lunch

Session II. Surgery of NSCLC (Chairman: Zo Jae-Ill, MD)
13:00-13:40 Current surgical approach to NSCLC at MSKCC*(Robert Downey, MD)
13:40-14:00 Surgical result and regrouping of stage IIIA NSCLC(Lee Hae-Won, MD)
14:00-14:20 Surgery of mediastinal T4 NSCLC(Baek Hee-Jong, MD)
14:20-14:30 Discussion
14:30-14:45 Coffee break

Session III. Recent Advances in Management of NSCLC
(Chairman: Kim Sung-Rok, MD)
14:45-15:25 Time to "TARGET" lung cancer*(Mark Kris, MD)
15:25-15:45 Novel approach in radiotherapy: Cyberknife(Kim Mi-Sook, MD)
15:45-16:05 Management of locally-advanced NSCLC with surgery, radiation and chemotherapy(Mark Kris, MD)
16:05-16:25 Postoperative adjuvant chemotherapy(Kim Heung-Tae, MD)
16:25-16:45 Preventing emesis caused by cancer treatment: New tools to do a better job(Mark Kris, MD)
16:45-16:55 Discussion

( * lecture)


■ 2003년 10월 11일(토)
"Challenges in Colorectal Cancer: Past, Present and Future"

08:30-09:00 Registration
09:00-09:10 Opening remarks (Shim Youn-Sang, MD, Thomas Fahey, MD)

Session I (Chairman: Lee Jong-Inn, MD)
09:10-09:25 Epidemiologic haracteristics of CRC in Korea(Kim Dong-Hyun, MD)
09:25-09:40 5-Fluorouracil pharmacogenomics in patients with CRC(Kim Soo-Ok, PhD)

Session II. Presidential Address
09:40-10:10 History of the development of the first comprehensive cancer center in America(Thomas Fahey, MD)
10:10-10:30 KIRAMS' 40 years dedicated to cancer patient care in Korea
(Lee Soo-Yong, MD)
10:30-10:50 Coffee break

Session III (Chairman: Sohn Seung-Kook, MD)
10:50-11:05 Hepatectomy in liver metastasis of CRC(Kim Sang-Beom, MD)
11:05-11:30 Systemic vs. directed infusional therapy for hepatic metastases
(Nancy Kemeny, MD)
11:30-13:00 Lunch

Session IV (Chairman: Park Eung-Bum, MD)
13:00-13:15 Abnormality of apoptosis in CRC(Lee Ryung-Ah, MD)
13:15-13:30 Lung metastasis of CRC, optimal selection(Moon Sun-Mi, MD)
13:30-14:05 Molecular profiling of colorectal cancer: new methods and new biological insights(Philip Paty, MD)

Session V (Chairman: Woo Ze-Hong, MD)
14:05-14:20 Brain metastasis of CRC, rare but aggressive treatment?
(Kim In-Kyung, MD)
14:20-14:35 Novel approach in recurrent CRC: Cyberknife radiosurgery
(Kim Mi-Sook, MD)
14:35-15:00 Local excision of rectal cancer: Is there a future?(Philip Paty, MD)
15:00 - 15:10 Coffee break

Session VI (Chairman: Chun Ho-Kyung, MD)
15:10-15:25 Angiogenesis in CRC, from laboratory to bed(Hwang Dae-Yong, MD)
15:25-15:50 Multimodality management of advanced rectal cancer: What's important?
(Philip Paty, MD)

Session VII (Chairman: Kim Young-Jin, MD)
15:50-16:05 Xelox study in stage IV CRC, preliminary result(Park Yeon-Hee, MD)
16:05-16:30 New options for treating metastatic colon cancer(Nancy Kemeny, MD)

Session VIII (Chairman: Lee Bong-Hwa, MD and Han Won-Kon, MD)
16:30-17:00 Case study & Discussion with Dr. Paty and Dr. Kemeny
Presentation: Kim Nam-Kyu, MD, Oh Seong-Taek, MD, Yu Chang-Sik, MD


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.